Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Peruvian ex-President Martin Vizcarra sentenced to 14 years in prison - 2Protest inspired by 'Gen Z' movement draws few young people in Mexico and many government critics
- 3Instructions to Help a Friend or family member Determined to have Cellular breakdown in the lungs
- 4New movies to watch this weekend: See 'The Drama' in theaters, rent 'Wuthering Heights,' stream 'Pizza Movie' on Hulu
- 5Ford Is Using a Chinese-Built Van to Fight Europe’s EV Price War
- How 2025 became the year of comet: The rise of interstellar 3I/ATLAS, an icy Lemmon and a cosmic SWAN
- Figure out How to Remain Informed about the Most recent Open Record Extra Offers
- Hundreds of Intact Dinosaur Eggs Emerge From 72-Million-Year Time Capsule
- Volkswagen Plant Could Pivot From Building Cars to Supporting Iron Dome Systems
- Understanding Preschool Projects: Cultivating Abilities and Advancement
- Which sandwich do you find totally delectable? !
- Pick Your #1 Sort Of Espresso
- What is the Insurrection Act? Can Trump really use the military to 'put an end' to Minneapolis ICE protests?
- The 1 question we have to ask ourselves about the Taylor Frankie Paul 'Bachelorette' scandal
